Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
The last earnings update was 54 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Vical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Vical's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Vical is high growth as no earnings estimate data is available.
Unable to determine if Vical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Vical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Vijay B. Samant has been the Chief Executive Officer and President of Vical Incorporation since November 2000. Mr. Samant joined Vical Inc. in November 2000. He served as Acting Chief Financial Officer of Vical Incorporated from April 12, 2013 to May 25, 2017. He has over 23 years of U.S. and International Pharmaceuticals experience in the areas of Sales, Marketing, Operations and Business Development. Previously, Mr. Samant held various positions at Merck & Co. Inc. from 1977 to 2000. From 1998 to 2000, he served as the Chief Operating Officer of the Merck Vaccine Division. He served as Chief Executive Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. From 1977 to 1990, Mr. Samant held a variety of positions of increasing responsibility in manufacturing, process engineering, production planning and control, business development and loss prevention in several Merck operating divisions. He has been a Non-Executive Director of AmpliPhi Biosciences Corporation since November 2015. He has been a Director of Vical Incorporated since November 2000. Mr. Samant was a member of the Board of Trustees for the International Vaccine Institute (IVI, Seoul, Korea) since 2008 to 2012 and a member of the Board of Trustees for the National Foundation for Infectious Diseases (NFID, Bethesda, MD) since 2003 to 2012. He served as a Director of Raptor Pharmaceuticals Corp, from April 13, 2011 to July 28, 2014 and a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010. He served as a Director of BioMarin Pharmaceutical Inc. from June 15, 2002 to May 4, 2004. Mr. Samant also serves on the Project Management Subcommittee of the International AIDS Vaccine Initiative. Mr. Samant holds an MBA from the Sloan School of Management at the Massachusetts Institute of Technology, an MS in Chemical Engineering from Columbia University and a BS in Chemical Engineering from the University of Bombay, University Department of Chemical Technology, India.
Vijay's compensation has increased whilst company is loss making.
Vijay's remuneration is higher than average for companies of similar size in Germany.
CEO, President & Director
VP, CFO & Chief Accounting Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Vical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.